PhoreMost announces lead oncology program and appoints Chief Medical Officer to support clinical entry

Key People Moves

▤ Summary

PhoreMost has named PMC-001 as its lead oncology program and is preparing to move the asset toward first-in-human trials. The company says the small molecule targets primary and secondary brain cancers and has completed CMC work and preclinical safety studies. PhoreMost also appointed Dr. Gabriel Fox as Consulting Chief Medical Officer to guide clinical development. The announcement signals progress from discovery into clinical-stage execution for an oncology pipeline asset.

▥ Classifications

industries
No industries detected
applications
No applications detected

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies